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Article Synopsis: This article describes a qualitative study using semi-structured interviews to 
explore pharmacists’ perceptions and communication strategies of the risks related to alertness 
impairing medications. Interviews were analysed using Framework Analysis and unveiled three 
key themes: Safety and Consequences of AIMs’, ‘Factors that Influence Risk Communication’ 
and ‘Refining Risk Communication’. Risk communication was perceived to be an important part 
of clinical practice but a number of factors influence   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
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Background: A core role of the pharmacist is to ensure safe and effective medication use. 
Therapeutic classes that impair alertness (e.g. sedatives or hypnotics) can pose safety concerns 
for the consumer when undertaking activities requiring psychomotor vigilance (e.g. driving).  
Objective:  To explore pharmacists’ perceptions and communication strategy of the risks related 
to alertness impairing medications in clinical practice.  
Methods: In-depth semi-structured interviews explored community pharmacists’ perceptions of 
medication-related risks, current medication provision and the feasibility of new practice tools. 
Interviews were digitally recorded, transcribed verbatim and analysed using Framework Analysis 
to identify emergent themes. A Psychometric Risk Perception Questionnaire was also used to 
evaluate pharmacists’ perceptions across 7 common   psychotropic drug classes.  
Results: Synthesis of the qualitative dataset of 30 pharmacist interviews revealed three key 
themes: ‘Safety and Consequences of AIMs’, ‘Factors that Influence Risk Communication’ and 
‘Refining Risk Communication’. Participating pharmacists were generally aware of the 
therapeutic classes associated with medication-related risks but were concerned about patients’ 
level of understanding. Counselling approaches were largely dictated by perceived patient 
interest/experience with a medication. Concerns were centred on inter-individual 
pharmacokinetic differences, which could make the precise risk assignment difficult. 
Pharmacists also highlighted workflow limitations and the need to bring patients’ attention to 
these resources during the clinical interaction to maximise impact.  
Conclusions: Medication-related risk communication is a complex clinical phenomenon dictated 
by patients’ prior experiences and the pharmacists’ practice environment. Extending the evidence 
base in this therapeutic area and refining clinical resources are key steps towards optimising 
patient medication safety.  
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1 AIMs: Alertness Impairing Medications  
  DRUID: Driving Under the Influence of Drugs, Alcohol and Medicines in Europe 
  EPPM: Extended Parallel Process Model 
  TAC: Transport and Accident Commission  
  TGA: Therapeutic Goods Administration  
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Attentional deficit, which involves deficits in concentration, alertness or vigilance, is a serious 
adverse effect that results directly from medications that affect the central nervous system such 
as psychotropic medications (e.g. hypnotics) or indirectly from the blood-pressure/glucose 
lowering effects of anti-hypertensive and anti-diabetic agents respectively. The latter group is 
especially problematic as health professionals or consumers alike may be indifferent to the 
impairing effect of the medication. 1 These medications may be referred to as Alertness 
Impairing Medicines (AIMs).  
 
Undertaking any activity relying on psychomotor vigilance whilst using a medication that may 
impair alertness can have important safety implications for the patient. Worldwide, road traffic 
authorities warn against the use of medications causing impaired psychomotor vigilance whilst 
driving. The impact of AIMs on driving (e.g. slow reaction time and decreased motor 
coordination) is highlighted through reports of traffic accidents and simulated driving 
experiments. For example, in the US, a 2010 nationwide study found that 46.5% of drivers who 
tested positive for drugs after a fatal accident had used a prescription medication, with 
benzodiazepines or opiates most implicated;2  similar findings have been reported from Europe, 
Canada, and Australia. 3-5 Driving impairment is only one example of the detrimental effects of 
AIMS. Particular classes of AIMs medications, such as sedatives antidepressants and 
antipsychotics have been implicated in falls and fractures.6 Sedatives such as benzodiazepines 
have been linked with an increased mortality.7 Although as yet inconclusive, recent research 
studies have also investigated the link between benzodiazepines and cancer,7 dementia 
development,8 as well as nosocomial infection 9in critically patients. Newer sedatives such as the 
Z-drugs have also been linked to serious neuropsychiatric consequences such as parasomnias e.g. 
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sleepwalking.10, 11 Many AIMs are also often implicated in cases of accidental poisoning. 12  
Much research in the area of risk management (e.g. drugs and driving)focuses either on 
medication misuse rather than use or on de-prescribing interventions.  Given the increasing 
burden of chronic disease and ageing populations in the developed world, legitimate use of AIMs 
is a palpable concern.  
 
Often the final interface between an AIM user and a health professional is the pharmacist, who 
has an ethical, clinical and legal responsibility to ensure consumers are well informed about the 
effects of AIMs and take appropriate measures to minimise risk.  However, effective risk 
communication is influenced by various factors, key amongst them, are effective tools that assist 
in the communication process. These tools include 1) specific product information (PI)/consumer 
medicines information (CMI) provided to patients 2) the use of ancillary warning labels affixed 
on the product container 3) Risk related counselling and communication.  Specific knowledge 
about medications and their extent or type of alertness impairment would be a factor that can 
enhance risk related counselling. In Europe, this has been realised through the Driving Under the 
Influence of Drugs, Alcohol and Medicines (DRUID) project. One arm of this project relates to 
categorising individual medications into different levels of driving impairment i.e. Category I, II 
& III (minor, moderate & severe) and detailing specific information to facilitate individualised 
counselling about the medications’ effect on driving for users.13 In Australia, the Transport 
Accident Commission (TAC) utilises similar categories proposed by the International Council on 
Alcohol, Drugs and Traffic Safety (ICADTS),14  but this classification is not widely 
disseminated/integrated within pharmacy dispensing programs.  
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Other key factors that may affect the risk communication by pharmacists to AIM users may be 
the risk perceptions and perceived efficacy of recommended risk limiting actions by the 
recipients of the communication (e.g. AIM users).  Several frameworks to understand how 
individuals perceive risk and respond to risk communication have been developed and used 
understand risk perception, so as to develop effective messaging about risk mitigation to 
consumers. One such framework is the Extended Parallel Process Model (EPPM). The Extended 
Parallel Process Model (EPPM), 15, 16 suggests that when individuals are faced with risk 
prevention messages, they consider whether the threat is serious/real and whether they are 
susceptible to its potential impact. If the threat is perceived as real and the individual perceives 
susceptibility (i.e. the medication will affect my alertness, and can impair my driving skills), then 
a further assessment of efficacy is undertaken, specifically, whether the risk prevention message 
contains information that can help the individual to avoid the threat (i.e. if I avoid driving for 24 
hours after taking this medicine, I will be safe). This latter appraisal is twofold, with an 
assessment of the usefulness of the information (response efficacy) and one's self-efficacy 
(ability, capability, and access).15   
 
The response following the appraisal can be either ‘fear control’ or ‘danger control’. Fear control 
is an emotional response by which the individual seeks to eliminate fear, without eliminating the 
causative risk; this response is more likely if the threat or susceptibility associated with the risk is 
higher than impressions about self or response efficacy (i.e. I will not drive at all but will 
continue to use this medication).16  Danger control is a more rational response, where the 
individual seeks to eliminate the cause of the risk, this response is more likely if the perceived 
threat or susceptibility about the risk are assessed to be lower than self or response efficacy by an 
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individual (i.e., I will use this medication only if needed, and time my driving carefully to be in 
periods where my driving will not be affected by the medicine).15 
 
 Patel, Barnett 17 (2011) describe how the EPPM can be used by pharmacists. In their study, they 
trained pharmacists on strategies such as the use of universal statements and open ended 
questioning which was used with a view to counsel male patients about health risk factors. 17  
These strategies allowed participating pharmacists in their study to minimise ‘fear’ whilst 
controlling feelings of ‘vulnerability’ whilst motivating patients about their self and response 
efficacies.17 Whilst much of the EPPM focusses on the recipients of the risk communication, it 
may be posed that providers are perhaps also subject to the same processes. For example, their 
level of risk perception and perception about the usefulness of the message they communicate 
and beliefs about their own ability to convey a message effectively can affect uptake of the risk 
minimisation strategies conveyed.   
 
Australian pharmacists currently draw on a set of generic, albeit well established, counselling 
protocols, reference texts and mandatory labelling requirements (Fig.1) during the provision of 
AIMs. However, little is known about the perceived usefulness of these clinical resources or how 
pharmacists might delineate and communicate AIM related risks to the consumer. Therefore, the 
aim of this study is to explore pharmacists’ perceptions of risk and safety with regards to the 
provision of AIMs in routine clinical practice and to explore the feasibility of implementing new 
clinical resources for refining risk communication. 
 
 
Material and methods 
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Design  
Individual semi-structured interviews were conducted either face-to-face or via telephone by the 
first and second authors. The interviews were guided by a schedule of questions that was 
informed by a review of the relevant literature on the attentional deficits of medication use and 
on risk communication frameworks (Table 1).  The key focus of the interview  explore 
pharmacists’ provision of AIMs, their perception of consumer risk awareness associated with 
AIMs, the perceived effectiveness of their risk communication messages and the need/feasibility 
of integrating new resources into clinical practice. To stimulate discussion of the latter, a new 
warning label design based on previous research in France was used as a discussion prompt. 18 
Data collection proceeded until thematic saturation was achieved (i.e. ensuing interviews did not 
provide additional themes/concepts around AIMs provision). Interviews were digitally recorded, 
transcribed verbatim and analysed for emergent themes. In addition, a psychometric risk 
perception scale adapted from a patient-focused study by Slovic, Peters, Grana, Berger, Dieck 19  
was used to quantify the perceived risks across the different therapeutic classes of AIMs among 
pharmacists.   
 
The scale is based on the psychometric paradigm, originally proposed by Slovic, Peters, Grana, 
Berger, Dieck 19 which posits that risk perception can be quantified by asking people to make 
quantitative judgments about the relative riskiness of various hazards.19 The original instrument 
assessed consumer perceptions around 53 medical risk items (including pharmaceutical products 
both prescription or over the counter, as well as medical tests, procedures and devices) across 5 
key characteristics of risk. These characteristics include:  1) risk 2) benefits 3) seriousness of 
harm in an accidental exposure 4) the extent to which risks are known to those exposed and 5) 
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whether serious problems if occurring in those exposed would serve as warning signs.  For the 
purpose of the current study, the item on ‘warning signs’ was omitted, given that all pharmacists 
are trained on pharmacovigilance and reporting adverse events is a part of their professional role, 
which fact may have biased their responses on this item. Further, each item was framed around 
pharmacists’ perceived consumer awareness of the respective dimensions, rather than their own 
perceptions. The scope of the current study also focused on medication classes where 
pharmacists would normally need to warn patients about sedation and potential attentional 
deficits.  An additional class of complementary sleep aids were also included to broaden the 
scope of the study (Appendix 1).  It may be noted that the main intent of the study was the 
qualitative exploration of pharmacists risk perceptions. The psychometric risk perception scale 
was used merely to clarify in our qualitative method paradigm whether quantified risk perception 
could offer any explanation of variable responses in the participant’s interview data. The study 
protocols and materials were approved by the University of Sydney Human Research Ethics 
Committee (HREC Protocol #2014/1020).  
 
Participants and Settings 
A convenience sample of community pharmacists known to the researchers were initially 
recruited throughout metropolitan Sydney, New South Wales and Perth, Western Australia. 
Following this initial recruitment, a passive snowballing technique was used whereby initial 
participants were asked to discuss the study within their professional networks and interested 
colleagues were encouraged to contact the researchers directly. Participants were offered $30 gift 
vouchers for their involvement in the study.  
 
Pharmacists and Risk Communication  
11 
Data Analysis  
Interview transcripts were subjected to Framework Analysis (FA) as described by Ritchie, 
Spencer 20  using QSR NVivo 10 software. FA evolved out of applied social policy research and 
allows for the incorporation of diverse perspectives on a given phenomenon and involves five 
key stages (consisting of familiarization where interview transcripts and field notes were 
iteratively to identify emergent concepts. These emerging concepts were combined with the a 
priori issues outlined in the interview guide to form the basis of the preliminary thematic 
framework. Three researchers independently read and coded initial transcripts (n=5) against the 
preliminary thematic framework. New thematic categories or discrepancies were discussed at 
subsequent research meetings to further develop the thematic framework.  The next stage 
involved indexing where the final thematic framework is systematically applied to each 
transcript to identify relevant units of text that were indexed corresponded to a particular theme. 
Indexed data were further abstracted and charted into thematic matrices containing the related 
thematic categories. In the final stage, mapping and interpretation, cross-case and within-case 
relationships were identified and discussed with the research team for abstraction into a set of 
emergent themes. 21, 22  
 
Results 
Data saturation was achieved at 30 interviews.  Participant demographic data are highlighted in 
Table 2. Analysis of the qualitative data identified three main themes: Safety and Consequences 
of AIMs, Factors Influencing Risk Communication and Refining Risk Communication. After 
completing the analysis, the thematic structure was qualitatively analysed for any patterns 
explainable by demographic or psychometric risk score variation; this was done by reading each 
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transcript again with the framework and demographic characteristics of that participant imposed 
on the transcript. This subjective analysis did not result in the identification of any discernible 
difference in responses between genders or various pharmacy roles (e.g. manager vs. locum). 
Relevant participant quotes have been included for the respective themes and sub-themes to 
support our findings.  Quotes have been assigned codes to indicate gender (denoted by M and F), 
participant’s unique number and years of practice (F#Y# or M#Y#).  Participant responses on the 
Psychometric Perception Questionnaire are highlighted in Figure. 2. 
 
Theme 1: Safety and Consequences of AIMs 
Subtheme 1.1:  AIMS Risk and Harm 
The majority of participants identified AIMs as medications perceived to pose a serious safety 
risk to consumers, stressing on the possibility of side effects (particularly in terms of drowsiness) 
and expressing a strong concern for the likelihood of tolerance and dependency. The participants 
mainly conveyed their concerns in relation to the risks associated with driving a motor vehicle 
under the influence of AIMs and they often did not elaborate upon other activities that may be 
compromised (e.g. working with machinery/tools or leisure activities such as swimming etc.)  
“Definitely, I think drugs can affect a person’s ability to drive, in some people it can have very 
severe consequences and it needs to be a lot more recognised and it needs to be in the same 
category as alcohol when we talk about driving.” (M8Y6) 
 
Subtheme 1.2: Consumer and Medication variability 
Participants recurrently emphasised that AIM related risks are complicated by the varying extent 
to which these agents inherently influence psychomotor vigilance, the nature of the activity 
undertaken by the patient, inter-individual patient differences and concomitant medication 
use/history. They noted how variations in pharmacogenomics and pharmacokinetics such as 
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faster or slower medication metabolism could lead to individuals reacting differently to 
medications. Therefore they considered that some could experience side effects of ‘profound 
drowsiness’ whilst on these medications and others could maintain ‘normal’ motor function. This 
led to uncertainty when counselling. Certain drug classes were perceived to pose greater risks, 
particularly sedatives, hypnotics and analgesics. It was evident that non-prescription Over-the-
Counter (OTC) AIMs were key concerns for participants, particularly codeine-containing and/or 
sedating antihistamines (e.g. doxylamine succinate) due to the high prevalence of consumer 
requests. Interestingly, despite this expression, participants’ mean ratings of the risk for OTC 
categories were scored lower than that for prescription medications (Figure 2).  
“People tolerate things differently to other people, certain medications can be tolerated by 
certain people and some can’t and again there are certain medications that we know you can 
build tolerance to sedation or even pain tolerance, so they would need increased doses to get the 
same effects.” (M14Y10) 
 
 
Theme 2: Factors that Influence Risk Communication 
 
Subtheme 2.1: Perceived Consumer Beliefs and Actions 
Successful risk communication was seen as contingent on consumers’ health literacy levels, 
whereby they were perceived to have little awareness towards the risks associated with AIM use. 
Participants considered that consumers were influenced into taking AIMs from a number of 
sources including friends, family and from the Internet. These sources were viewed to skew the 
expectations of consumers when requesting an AIM. They suggested that consumers believe that 
these medications ‘solve’ a number of their ailments, whilst underestimating possible risks, 
specifically regarding non-prescription/OTC products. However our participants also indicated 
that beliefs differ and that some consumers were perhaps more concerned for their health and 
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therefore questioned more about their medications than others and their decisions to use AIMs 
were based on reasonable estimates of benefits versus risks.  
 
Participants expressed that the role they play is often limited by external factors, suggesting that 
counselling does not necessarily correlate with consumers’ actions (e.g. driving under the 
influence of an AIM). Chronic AIM users were mainly portrayed as those dependent and tolerant 
to most effects of the medication; therefore they were considered more likely to ignore 
pharmacists’ concerns. They also indicated that it is often difficult to warn consumers about the 
risks associated with their medication, particularly due to the fear of decreased adherence or 
abrupt withdrawals.  
 
“Some people have strong beliefs of medication… I would say one of the hard points is that 
 we actually need to change the perception of the patient.”  (F17Y5) 
 
Subtheme 2.2: Professional Practice and Regulation 
Participants identified their role as being responsible for educating consumers about the risks of 
AIMs and signified the importance of this task from a moral and ethical viewpoint to ensure 
consumer safety, and also from a legal viewpoint to protect the pharmacist from possible liability 
or indemnity. Most participants exhibited a strong faith in the current regulations and practice 
standards surrounding the provision of AIMs, however application was considered difficult 
suggesting that certain aspects of community practice make them incommodious. The main 
issues raised were related to time and the busy work environment that prevented them from 
providing consumers with the necessary information required to ensure the safe use of 
medications. 
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“Most pharmacists find it difficult because they are restricted by time to go through   
[information] in more details…” (F12Y18) 
 
 
Subtheme 2.3: Tools and Resources 
Participants indicated that the main tools available to communicate risks with regards to AIMs 
were cautionary advisory labels and Consumer Medicines Information (CMI) printouts. The 
main label mentioned was the ancillary warning label 1 (L1), which is a mandatory component 
for the supply of medications that may cause sedation or drowsiness in Australia. According to 
participants, other labels (L1a and L12 (Figure 1)) were less often used and considered difficult 
to differentiate from L1. A major limitation perceived by participants regarding labels was the 
perception that consumers do not read or notice these labels, most likely negating any possible 
benefits.  
 
When probed about which resources they use to determine the risks of medications, participants 
indicated that they prefer what is easily accessible and available, with the majority using eMIMs 
(Monthly Index of Medical Specialities) as their main or sole source of information. Current 
tools and resources were considered lacking in details that may contribute to risk 
communication, such as duration of effect or severity of risk. 
 
“No one has ever asked me about the L1 label, no one has ever asked me about the L12 label, no one 
has ever brought labels to me. No one reads boxes from all my experience. It is me delivering it, as I 
am giving it out and talking about it.” (M18Y8) 
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Theme 3: Refining Risk Communication 
Subtheme 3.1: Government and Organisation 
Most participants were content with the current practice/legislations in pharmacy and considered 
them sufficient, however a need for improved resources or tools that could improve risk 
communication was emphasised. When juxtaposed with the media and government focus on 
driving under the influence of alcohol, participants considered that similar efforts should be 
enacted regarding the effects of AIMs on driving. The majority stressed the importance of 
government and organisational intervention via the use of campaigns or media in order to 
increase the consumers awareness of the possible risks associated with AIMs and to warn that 
misuse can result in consequences. The majority opposed increased regulations within the 
community pharmacy setting but suggested that the involvement of law enforcement in the 
public setting could possibly deter potential abusers or misusers of such medications. 
“I think it’s pretty clear that the authority has made it quite clear about the low tolerance with 
drinking and driving. You need to be under a certain threshold to be able to drive, I think the same 
should apply to medications so they are known to have an effect on peoples concentration and their 
ability to maintain alertness” (F4Y5) 
 
Subtheme 3.2: Counselling 
Participants indicated that although consumers vary in their response to AIMs, it is often difficult 
to tailor counselling to this fact. However they generally concluded that it falls upon a 
pharmacist’s judgement and relationship with the consumer to identify whether brief counselling 
or an extended consultation is necessary. A large emphasis was placed on the importance of 
verbal communication. Written materials (e.g. labels, leaflets) were also mentioned as being 
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important because they can be used to reinforce certain points and act as reminders to the 
consumer. 
 
“The role of the pharmacist would be to verbally reinforce what has already been depicted on the 
label and offcourse the labels would form a reminder and particularly with S3 products the 
pharmacist must always provide counselling and when they take it home all they see is what is on the 
box, they may not remember what the pharmacist said... It’s my message that is going to make a 
difference, the way I deliver the message is going to make a difference, my body language is going to 
make a difference and my connection to you is going to make a difference. The way I talk as a human 
and the way I deliver my message, the way I interact with you on a personal level is everything. 
(F10Y4) 
 
At an explicit level, participants’ portrayed confidence in their skills and abilities. However,   uncertainty 
was a distinctly resounding theme that participants unconsciously echoed throughout the interviews. It 
was evident in most aspects discussed with participants, ranging from their ability to individualise, assess 
and communicate AIMs related risk to the effectiveness of current tools and resources. 
 
Whether what consumers actually take from what we say and whether what we are saying is 
actually enough or whether we need to do more, its currently unknown and I think it should be 
investigated. (M5Y3) 
 
Subtheme 3.3:  Labelling 
Regarding labelling, participants unanimously stressed on the importance of drawing the 
consumers attention to the warning labels whilst counselling, as the labels are often lost among 
the busy medication packaging. There were two main opposing opinions, which were to either 
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make the contents of the labels more detailed, or to simplify the labels into a more succinct and 
comprehensible message. Suggestions for the current label included: increased font size, the 
addition of graphics and highlighting/bolding certain words to emphasise their importance. Some 
participants considered the current labels efficient but others even recommended customised 
labels for certain medications to accommodate for the variability in drug side effects between 
classes. A summary of the labelling preferences among participants are also presented in Table 2.  
 
“If we can tailor it, and be a bit more specific that would be nice. For example how long are the 
effects likely to last or something like that. That would be very beneficial, to put a time, a 
quantitative figure.” (F22Y32) 
 
Subtheme 3.4:  Resources and Training 
Most participants suggested a need for additional novel resources to help communicate risk, 
however some indicated that the current issue is one of ineffective (rather than a lack of) 
resources. While most considered themselves sufficiently trained in handling the provision of 
AIMs, there was some acceptability for increased training, particularly to improve their skills in 
communication with consumers. Support options such as a Call-Up information service 
dedicated to provide detailed and individually contextualised information received mixed 
responses with some recommending this potential resource yet others stating that time 
constraints, privacy issues and other factors would make it ineffective. Participants indicated the 
need for more research on AIMs and supported the idea to implement something similar to the 
DRUID project in Australia. They suggested that it would be successful as long as it was 
government/organisation supported and for such changes to be integrated into current tools and 
resources (e.g. dispensing software). 
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“It [DRUID] would be beneficial for the health professionals, such as the pharmacist who has to 
make the decision, so I think it would be more beneficial for the pharmacist to properly and clearly 
communicate their thoughts and if they ask why, then we can state that this is based on the 
parameters that we have here and it is self-explanatory.” (F20Y2) 
 
Discussion 
To our knowledge this is the first study to explore the factors influencing the provision and safe 
use of Alertness Impairing Medications (AIMs) by pharmacists. It extends on the current 
literature on medication safety and pharmacy practice with broader public health implications.  
To date, research on AIMs has been limited to economic and health related consequences (e.g. 
road traffic injury) and few studies focus on the point of medication supply (i.e. the pharmacist-
patient interaction). A recent report stresses the importance of the role that pharmacists play in 
the safe and effective use of AIMs and indicates the need for pharmacists to “reconsider how 
they are counselling patients on medication impairment”, 1 further supporting the importance of 
our approach.  
 
A salient message that reverberated throughout our participant interviews is that medication risk 
communication is a complex clinical phenomenon dictated by consumers’ prior experiences and 
the pharmacists’ practice environment. That risk communication is a complex process is well 
known; in the sociological literature, much research focusses on communication about general 
side effects in balance with benefits (e.g. for new or trial/investigational drugs). There is a 
paucity of drugs on the specific risk communication/counselling for drugs impairing alertness. In 
our study, participant concerns revolved around the possibility of traffic related accidents and the 
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overuse/misuse of non-prescription/OTC codeine-containing products. Participant frustration 
also stemmed from the dilemma between being aware of the misuse of AIMs and consumer 
misbeliefs about the risks of such medications. The issues, concerns and needs reported by our 
participants provide new insight for shaping potential novel strategies to facilitate Australian 
pharmacists in providing targeted and effective counselling to consumers using AIMs, ultimately 
enhancing public safety. 
 
A key issue highlighted in the study was the need for consumer engagement to improve risk 
awareness of AIMs. Perceptions of consumers ignoring warning labels is consistent with 
published literature related to Australian consumers 23 and globally.24, 25 To counter this, several 
studies have tested ways to enhance the noticeability of warning labels through depicting organ 
specific damage, 26 black-box warnings and the addition of text and colour 13.  One study 
comparing warning labels used in Australia and France concluded that participants were more 
readily able to delineate risk levels from the French labelling system due to the inclusion of 
medication risk categorisation and the effective use of colour and graphics. 18 Drawing form the 
patient-centred work of McCarthy, Davis, King, Mullen, Bailey, Serper, Jacobson, Parker, Wolf 
27 instruction labels containing action-terms (e.g. Take-Wait-Stop) as a means to ‘frame’ 
important behavioural precautions while using AIMs might be another approach for enhancing 
consumer engagement in a meaningful way. 27   
 
The need for more concerted efforts that triangulate public health action and increased 
informational support for health professionals were cited among our participants as key strategies 
for enhancing consumer awareness/engagement. The DRUID project exemplifies the latter 
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through refining information on risk categorisation of AIMs with respect to driving risks in all 
labelling and resources. Similar programs could be adopted in Australia, and may be beneficial 
in pharmacists’ counselling and decreasing the intrinsic possibility of consumers inaccurately 
assigning risks to different medication classes. Evidence-based information could also allay 
some of the uncertainty participating pharmacists exhibited regarding risk communication 
around AIMs. For example, a Belgian research group recently developed and tested detailed 
dispensing support electronically integrated with dispensing software for pharmacists and 
reported positive outcomes (i.e. increased frequency of pharmacist counselling and targeted 
information gathering concerning AIMs use).28 The successful legislative limits that have been 
introduced over the years to manage driving under the influence of alcohol can similarly be 
proposed for AIMs as suggested by our participants and recently implemented in Norway. 29   
 
In order to suggest new risk communication strategies or propose new educational processes, it is 
often important to investigate public health behavioural change theories. The results from this 
study of pharmacist perceptions directly align with the constructs of the Extended Parallel 
Process Model (EPPM) described in the introduction.15 In the case of pharmacists, they indicated 
that they consider their capability of communicating the risks of AIMs (efficacy), weighing it 
against the risks associated with the medication (perceived risk) and the additional fear of 
variable consumer response (e.g. disapproval or decreased adherence to medications) - all acting 
as strong motivators that influence the extent to which they use resources and/or spend time 
counselling. Pharmacists’ uncertainty about how a medication may affect the consumer may 
have also unconsciously affected the communication process. Furthermore, it is evident that the 
pharmacists’ perception of consumers follows a similar process, whereby consumers were 
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perceived to incorrectly assign the benefits and harms of AIMs (perceived risk), denying the 
need to receive more counselling due to ‘fear’ of being asked to stop a medication that they were 
reliant/dependent on and considering themselves capable of managing the risk (efficacy).  
 
In order to introduce new strategies to communicate AIMs risks, it is important to first 
understand how people form a meaningful understanding of risk in order to eventually 
implement evidence based methods that result in safe medication use. The EPPM has been used 
previously in attempts to warn consumers of other risks, using the notion of ‘fear’ through 
graphics and health promotion campaigns to effectively target issues such as smoking harm and 
even driving related risks (e.g. fatigue); it would be pertinent to explore the utility of this model 
in future research around pharmacists’ risk communication regarding alertness impairing 
medicines.30 Figure 3 outlines some suggested strategies to enhance the effectiveness of AIM 
related risk communication by pharmacists by applying the EPPM model constructs.  
 
Furthermore, the findings of this study resonate closely with the recent Australian regulatory 
proposal to reassign codeine-containing over the counter products to ‘prescription only’ by the 
Therapeutic Goods Administration (TGA) to address issues of misuse/abuse. Most of the 
participants observed that misuse of non-prescription/OTC codeine-containing analgesics was 
still a frequent problem despite previous regulatory changes, which mandated compulsory 
pharmacist involvement in the provision of such products. 31-33  Based on this experience, our 
participants unanimously rejected the need for new scheduling and indicated that this will not 
necessarily solve the overarching issue in the long term. There were suggestions of mandatory 
recording/reporting similar to that of pseudoephedrine, which has proven effective, 34  and the 
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need for more collaboration between General Practitioners and pharmacists in educating 
consumers on possible risks/harms.  
 
AIMs are indicated for the management of a range of conditions and this study investigated 
pharmacist perceptions of the processes involved in risk communication and opportunities for 
possible improvement. Given our sampling frame, the transferability of our findings is limited, 
warranting the need to extend our approach on a national (e.g. rural vs metropolitan) and 
international level (e.g. Canada and Europe due to similar healthcare systems). Furthermore, 
since the data analysed was obtained solely from the pharmacist viewpoint, there is a clear need 
for additional research involving the consultation of consumers. This would act as additional 
confimation and would help to accurately ascertain their level of awareness and to understand 
how they associate AIMs with risk. Another key area that would thoroughly assist future 
research is good instrumentation. For example, the psychometric perception questionnare utlised 
in this study is not a validated tool; currently a validated instrument that explores specific 
domains of medication risk is not available as validated tools utilised in similar research studies 
explore more generalised issues with respect to beliefs about medication use. 
 
Conclusion 
The themes identified from our participants indicate that in the context of AIMs, risk 
communication is a complex clinical phenomenon dictated by patients’ prior experiences and the 
pharmacists’ practice environment. Extending the evidence base in this therapeutic area and 
refining clinical resources are key steps towards optimising safe medication use in patients. 
 
Pharmacists and Risk Communication  
24 
 
 
 
Pharmacists and Risk Communication  
25 
 
References 
 
1. Sigona N, Williams KG. Driving under the influence, public policy, and pharmacy 
practice. Journal of Pharmacy Practice. 2014;28:119-123. 
2. Wilson Fernando A, Stimpson Jim P, Pagan Jose A. Fatal crashes from drivers testing 
positive for drugs in the US, 1993–2010. Public Health Reports. 2014;129:342. 
3. Legrand SA, Isalberti C, Linden TV, et al. Alcohol and drugs in seriously injured drivers 
in six European countries. Drug Testing and Analysis. 2013;5:156-165. 
4. Vingilis E, Wilk P. Medical conditions, medication use, and their relationship with 
subsequent motor vehicle injuries: examination of the Canadian National Population 
Health Survey. Traffic Injury Prevention. 2012;13:327-336. 
5. Drummer OH, Kourtis I, Beyer J, Tayler P, Boorman M, Gerostamoulos D. The 
prevalence of drugs in injured drivers. Forensic Science International. 2012;215:14-17. 
6. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a Risk Factor for Falls: Critical 
Systematic Review. The Journals of Gerontology Series A: Biological Sciences and 
Medical Sciences. 2007;62:1172-1181. 
7. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a 
matched cohort study. BMJ Open. 2012;2. 
8. Pariente A, de Gage SB, Moore N, Bégaud B. The Benzodiazepine–Dementia Disorders 
Link: Current State of Knowledge. CNS Drugs. 2016;30:1-7. 
9. Caroff DA, Szumita PM, Klompas M. The Relationship Between Sedatives, Sedative 
Strategy, and Healthcare-Associated Infection: A Systematic Review. Infection Control 
&#x0026; Hospital Epidemiology. 2016;37:1234-1242. 
Pharmacists and Risk Communication  
26 
10. Wong C, Marshall N, Grunstein R, et al. Spontaneous Adverse Event Reports Associated 
with Zolpidem in the United States 2003-2012. Journal of clinical sleep medicine: 
JCSM: official publication of the American Academy of Sleep Medicine. 2016. 
11. Ben‐Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA. Spontaneous adverse 
event reports associated with zolpidem in Australia 2001–2008. Journal of sleep 
research. 2011;20:559-568. 
12. Gunja N. The Clinical and Forensic Toxicology of Z-drugs. Journal of Medical 
Toxicology. 2013;9:155-162. 
13. Emich B, van Dijk L, Monteiro SP, de Gier JJ. A study comparing the effectiveness of 
three warning labels on the package of driving-impairing medicines. International 
Journal of Clinical Pharmacy. 2014;36:1152-1159. 
14. Verster JC, Mets MAJ. Psychoactive Medication and Traffic Safety. International 
Journal of Environmental Research and Public Health. 2009;6:1041-1054. 
15. Smith RA, Ferrara M, Witte K. Social Sides of Health Risks: Stigma and Collective 
Efficacy. Health Communication. 2007;21:55-64. 
16. Kahlor L. PRISM: A Planned Risk Information Seeking Model. Health Communication. 
2010;25:345-356. 
17. Patel PS, Barnett CW. Counseling Techniques to Address Male Communication 
Characteristics: An Application of the Extended Parallel Process Model. Journal of 
Pharmacy Practice. 2011;24:386-390. 
18. Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions 
of medication warnings about driving: a comparison of French and Australian labels. 
Traffic Injury Prevention. 2013;14:557-564. 
Pharmacists and Risk Communication  
27 
19. Slovic P, Peters E, Grana J, Berger S, Dieck GS. Risk perception of prescription drugs: 
results of a national survey. Drug Information Journal. 2007;41:81-100. 
20. Ritchie J, Spencer L. Chapter 9: Qualitative data analysis for applied policy research. In: 
Bryman A, Burgess RG, eds. Analyzing Qualitative Data London; New York: Routledge; 
1994:173-194. 
21. Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse Researcher. 
2011;18:52-62. 
22. Srivastava A, Thomson BT. Framework analysis: a qualitative methodology for applied 
policy research. JOAAG. 2009;4:72-79. 
23. Smyth T, Sheehan M, Siskind V. Hospital outpatients’ responses to taking medications 
with driving warnings. Traffic Injury Prevention. 2013;14:18-25. 
24. Goldsworthy RC, Schwartz NC, Mayhorn CB. Interpretation of pharmaceutical warnings 
among adolescents. Journal of Adolescent Health. 2008;42:617-625. 
25. Shiyanbola OO, Meyer BA, Locke MR, Wettergreen S. Perceptions of prescription 
warning labels within an underserved population. Pharmacy Practice. 2014;12:387. 
26. Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA’s new over‐the‐
counter acetaminophen warning label in improving consumer risk perception of liver 
damage. Journal of Clinical Pharmacy and Therapeutics. 2012;37:681-685. 
27. McCarthy DM, Davis TC, King JP, et al. Take-Wait-stop: A Patient-Centered Strategy 
for Writing PRN Medication Instructions. Journal of Health Communication. 
2013;18:40-48. 
Pharmacists and Risk Communication  
28 
28. Legrand S-A, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation 
of training and software support for patient counselling by pharmacists. International 
Journal of Clinical Pharmacy. 2012;34:633-643. 
29. Vindenes V, Jordbru D, Knapskog A-B, et al. Impairment based legislative limits for 
driving under the influence of non-alcohol drugs in Norway. Forensic Science 
International. 2012;219:1-11. 
30. Basil M, Basil D, Deshpande S, Lavack AM. Applying the Extended Parallel Process 
Model to Workplace Safety Messages. Health Communication. 2013;28:29-39. 
31. McAvoy BR, Tobin CL. Fatal misuse of codeine-ibuprofen analgesics in Victoria, 
Australia. The Medical Journal of Australia. 2014;200:150-151. 
32. Tobin C L, Dobbin M, McAvoy B. Regulatory responses to over‐the‐counter codeine 
analgesic misuse in Australia, New Zealand and the United Kingdom. Australian and 
New Zealand journal of Public Health. 2013;37:483-488. 
33. Hamer A M, Spark MJ, Wood Penelope J, Roberts Emily. The upscheduling of 
combination analgesics containing codeine: The impact on the practice of pharmacists. 
Research in Social and Administrative Pharmacy. 2014;10:669-678. 
34. Berbatis CG, Sunderland VB, Dhaliwal SS. Linked electronic medication systems in 
community pharmacies for preventing pseudoephedrine diversion: A review of 
international practice and analysis of results in Australia. Drug and Alcohol Review. 
2009;28:586-591. 
 
 
